TAAR1 and schizophrenia: Promising efficacy and safety results in patients with schizophrenia were reported for ulotaront, a TAAR1 agonist with additional 5-HT1A agonist activity, currently in Phase 3 clinical development [1,[5], [6], [7], [8], [9]].